$CRSP CRISPR Therapeutics AG Insider Trading Week 16/2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in CRISPR Therapeutics AG.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in CRISPR Therapeutics AG in week 16/2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Option Exercise | M | 1.81 | 2,294 | 4,152 | 218,093 | |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Option Exercise | M | 1.81 | 47,706 | 86,348 | 220,387 | |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Sell | S | 17.37 | 2,294 | 39,852 | 1,215,005 | 1.2 M to 1.2 M (-0.19 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Buy | M | 1.81 | 2,294 | 4,152 | 1,217,299 | 1.2 M to 1.2 M (+0.19 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Sell | S | 18.61 | 15,368 | 285,988 | 1,215,005 | 1.2 M to 1.2 M (-1.25 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Sell | S | 17.57 | 32,338 | 568,078 | 1,230,373 | 1.3 M to 1.2 M (-2.56 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Novak Rodger | Chief Executive Off ... | Buy | M | 1.81 | 47,706 | 86,348 | 1,262,711 | 1.2 M to 1.3 M (+3.93 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 2,800 | 5,068 | 311,654 | |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 7,258 | 13,137 | 314,454 | |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 17.36 | 2,800 | 48,621 | 134,047 | 136.8 K to 134 K (-2.05 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 2,800 | 5,068 | 136,847 | 134 K to 136.8 K (+2.09 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 18.54 | 2,449 | 45,393 | 134,047 | 136.5 K to 134 K (-1.79 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 17.54 | 4,809 | 84,361 | 136,496 | 141.3 K to 136.5 K (-3.40 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 7,258 | 13,137 | 141,305 | 134 K to 141.3 K (+5.41 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 17.37 | 2,937 | 51,025 | 195,027 | 198 K to 195 K (-1.48 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 18.58 | 2,310 | 42,916 | 197,964 | 200.3 K to 198 K (-1.15 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 17.49 | 4,930 | 86,249 | 200,274 | 205.2 K to 200.3 K (-2.40 %) |